| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0004 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0004 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0008 |